GSK Stock Recent News

U.S. President Donald Trump sent letters to the chief executives of 17 major pharmaceutical companies, urging immediate action to lower the cost of prescription drugs for Americans, the White House said on Thursday.

President Donald Trump said he asked major pharmaceutical companies to take steps to cut U.S. drug prices within the next 60 days. It comes after Trump in May signed an executive order reviving a controversial policy that aims to slash drug costs by tying the prices of some medicine in the U.S. to the significantly lower ones abroad.

GSK plc (NYSE:GSK ) Q2 2025 Earnings Conference Call July 30, 2025 7:00 AM ET Company Participants Deborah Jayne Waterhouse - CEO of ViiV Healthcare & President of Global Health Emma Natasha Walmsley - CEO & Director Julie Belita Brown - CFO & Executive Director Luke V. Miels - Chief Commercial Officer Tony Wood - Chief Scientific Officer and Head of R&D Conference Call Participants James Daniel Gordon - JPMorgan Chase & Co, Research Division Kerry Ann Holford - Joh.

GSK's Q2 earnings and revenues top forecasts, with Specialty Medicines and Vaccines driving growth and a raised 2025 outlook boosting shares.

Emma Walmsley, GSK CEO, joins CNBC's 'Squawk on the Street' to discuss the company's most recent earnings, innovation pipeline, the potential impact of tariffs on pharmaceuticals, and much more.

GSK PLC (LSE:GSK, NYSE:GSK) delivered a strong set of second-quarter results, beating expectations on sales, profits, and earnings per share, and raised its guidance to the top end of its previous range. However, UBS analysts caution that much of this outperformance was driven by timing effects, such as early HIV medicine orders and stock builds, particularly in France for the Shingrix vaccine, which are likely to reverse later in the year.

GSK PLC (LSE:GSK, NYSE:GSK) said on Wednesday it expects to deliver results at the top end of its guidance for the year after reporting a robust second quarter, fuelled by strong sales in its Specialty Medicines and Vaccines businesses. The pharmaceuticals giant posted sales of £8 billion for the three months to June, up 6% at constant exchange rates.

British drugmaker GSK said on Wednesday it expects to report annual sales and profit towards the top end of its forecast range, adding that its outlook includes the impact of tariffs in place so far and expected levies on European goods.

GSK's diversified portfolio and strong HIV/specialty medicines offer stability, but growth prospects remain modest amid stiff competition and legal overhangs. Despite a robust pipeline and management's long-term revenue targets, I see limited near-term catalysts to drive significant EPS or share price appreciation. Financials reveal rising inventories and a stretched balance sheet compared to peers, making the current valuation potentially a value trap.

NEW YORK, July 28, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GSK plc (“GSK” or the “Company”) (NYSE: GSK).  Such investors are advised to contact Danielle Peyton at  newaction@pomlaw.com  or 646-581-9980, ext.